Newstral
Article
jdsupra.com on 2022-05-20 19:26
Teva Receives Approval for First Ophthalmology Biosimilar in Europe
Related news
- STADA and Xbrane Announce Approval of Ranibizumab Biosimilar in Europejdsupra.com
- Teva and Alvotech’s Adalimumab Biosimilar Receives Interchangeable Status at FDAjdsupra.com
- Biosimilar Approval Updates in Europe and Chinajdsupra.com
- Pfizer Receives European Approval For Avastin® (Bevacizumab) Biosimilarjdsupra.com
- Celltrion’s Herceptin Biosimilar Submitted For Approval in Europejdsupra.com
- Sanofi Receives Positive Opinion for Insulin Aspart Biosimilar in Europejdsupra.com
- Biosimilar Buyouts: AbbVie Buyout of Allergan Receives Approval of Irish High Court; Gedeon Richter Buys Tocilizumab Biosimilarjdsupra.com
- Samsung Bioepis Seeks Regulatory Approval for an Adalimumab Biosimilar in Europe and South Koreajdsupra.com
- Alvotech and STADA obtain approval in Europe for ustekinumab biosimilar, UZPRUVOjdsupra.com
- Centus Biotherapeutics Receives Positive Opinion for EQUIDACENT (Bevacizumab Biosimilar) in Europejdsupra.com
- VW receives approval to fix diesel cars in EuropeChicago Tribune
- Krystal Biotech receives approval in Europe for gene therapy treatmentbizjournals.com
- FDA Approval of Alvotech/Teva Ustekinumab Biosimilarjdsupra.com
- Biologic and Biosimilar Approval Updatesjdsupra.com
- Rituximab Biosimilar Updates from Europejdsupra.com
- 2017 Biosimilar Approvals in Europejdsupra.com
- Teva and Celltrion Launch Rituximab Biosimilar in USjdsupra.com
- Teva and Celltrion Launch Trastuzumab Biosimilar in U.S.jdsupra.com
- Teva and Alvotech Announce Partnership in the U.S. Biosimilar Marketjdsupra.com
- Sandoz Obtains FDA Approval for Adalimumab Biosimilarjdsupra.com